When patents become assets in the wrong place
Kien, founder of an AI company with its development team in Ho Chi Minh City, has just closed a new funding round. The investor sets one condition: the entire patent and software portfolio must be held by a holding company in a jurisdiction with a preferential tax regime for intellectual property income, known as a patent box. Two names are put on the table: Singapore and Malaysia. Kien realises this is not a contest over which headline rate looks lower on paper, but a test of substance: where does the research and development actually take place.
1. Singapore: an OECD-standard patent box at 5%, 10% or 15%
Singapore operates the Intellectual Property Development Incentive (IDI), a patent-box-style regime applying a concessionary rate of 5%, 10% or 15% to qualifying IP income. The key points:
- Scope: royalties and income from the commercial exploitation of patents and copyright subsisting in software elected into the regime.
- Nexus mechanism: the proportion of income qualifying for the concession follows the OECD modified nexus approach, tied directly to qualifying R&D expenditure undertaken by the company itself in Singapore. Acquiring ready-made IP or fully outsourcing R&D sharply reduces the qualifying portion.
- Substance requirements: the company must demonstrate skilled headcount and commensurate total business expenditure in Singapore; election of IP into the regime is irrevocable and made through tax filings.
In short, Singapore rewards companies that genuinely research and commercialise IP in Singapore, not a parking spot for patents bought elsewhere.
2. Malaysia: no standalone patent box; incentives follow the project
Malaysia does not operate a general patent box open to all companies. Instead, tax benefits for IP income are attached to specific investment promotion schemes:
- Malaysia Digital status: for digital technology, software and AI companies, with income tax exemption packages including benefits linked to digital IP income.
- BioNexus status: for biotechnology and life sciences, with tax exemption on qualifying IP income.
- MIDA incentives: pioneer status or investment tax allowance for qualifying projects, with substance conditions.
- New outcome-based framework: according to international tax advisory summaries, Malaysia is rolling out a results-based incentive framework offering a 0% rate on qualifying IP income for new investment projects meeting additional conditions. Because this framework is new, companies must check MIDA and tax authority guidance in force before planning around it.
The common thread across Malaysian schemes: R&D must be performed in Malaysia, IP must be registered with MyIPO or an equivalent body, and the company must meet the science-and-technology staffing ratios of each programme.
3. Three deciding questions
Question 1: Where is the R&D performed? If the research team sits in Singapore, the IDI is the natural fit. If the R&D centre is in Malaysia, Malaysian schemes do the work. Placing an IP holding where no R&D happens is a certain route to disqualification.
Question 2: Is the IP commercialised or still on paper? A patent box only matters once IP generates royalties. For an unexploited portfolio, prioritise protection and commercialisation first, tax optimisation second.
Question 3: Is the compliance cost worth it? Both jurisdictions demand nexus documentation, R&D cost tracking per IP asset and periodic reporting. With annual royalty flows below a few hundred thousand US dollars, the cost of running a compliant IP holding can swallow the tax saved.
4. Do not forget the double tax treaty
Cross-border royalties suffer withholding tax in the payer’s country, and the effective rate depends on the double tax agreement (DTA) in force between the relevant countries at the time of payment. Before finalising the structure, confirm the bilateral treaty exists and the royalty rate it provides; never assume from memory or outdated materials.
Conclusion
For Kien, the answer depends on where his AI team actually works. R&D in Singapore points to the IDI at 5% to 15%, a clear proven framework; a Malaysian development centre points to securing the appropriate status and meeting substance conditions. Either way, the golden rule stands: IP tax incentives are only for IP created by real activity, in a real place.
Frequently asked questions
Can we buy patents and place them in an IP holding to enjoy the patent box?
Not effectively. Both Singapore’s nexus mechanism and Malaysia’s schemes tie benefits to R&D expenditure undertaken by the company itself. Acquired IP is excluded or sharply reduces the qualifying income portion.
Does software count as qualifying IP?
Yes, as copyright subsisting in software. Both Singapore’s IDI and Malaysia’s schemes cover software copyright alongside patents. Trademarks are generally outside patent-box scope.
Does registering IP in a country secure the incentive there?
Not that simple. Singapore does not require local registration for the IDI but requires the R&D to be done in Singapore. Malaysia requires registration with MyIPO or an equivalent body plus Malaysian R&D. Registration location is only one of several conditions.
Does an IP holding need real staff in the holding jurisdiction?
Yes, that is the core substance requirement. Singapore requires skilled headcount and commensurate expenditure; Malaysian schemes set minimum science-and-technology staffing ratios. A holding with only a registered address will not survive review.
FLAT Law Firm supports technology companies
A cross-border IP holding structure requires coordinating IP law, tax law and double tax treaties. FLAT Law Firm helps companies assess substance, choose the right jurisdiction and build nexus documentation from day one.
This article has been quality-reviewed by the FLAW AI Legal Council
